产品名称
C18 Dihydroceramide (d18:0/18:0), Avanti Research™ - A Croda Brand 860627P, powder
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 25 mg (860627P-25mg), pkg of 1 × 5 mg (860627P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 860627P
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
OC[C@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)[C@]([H])(O)CCCCCCCCCCCCCCC
InChI
1S/C36H73NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h34-35,38-39H,3-33H2,1-2H3,(H,37,40)/t34-,35+/m0/s1
InChI key
KZTJQXAANJHSCE-OIDHKYIRSA-N
General description
C18 Dihydroceramide (d18:0/18:0) or N-Stearoylsphinganine is a synthetic lipid. Acylation of sphinganine with stearoyl (FA-CoA with C18 acyl chain) by dihydro ceramide synthase 1, yields C18-dihydroceramide.
Application
C18 Dihydroceramide (d18:0/18:0) has been used as a standard for the quantitation of sphingolipid metabolites in adipose tissues by quadrupole time-of-flight (Q-TOF) mass spectrometry.
Biochem/physiol Actions
Dihydroceramides act as precursors for ceramides in the mammalian de-novo sphingolipid pathway. vitamin D supplementation increases plasma C18 dihydroceramide (C18-DHC) levels in type 2 diabetes mellitus (T2D) patients. Low serum concentration of C18-DHC has been observed in patients with history of graft rejection and ischemic type biliary lesions (ITBL). Therefore, it can be used as a predictor of graft rejection.
Packaging
5 mL Amber Glass Screw Cap Vial (860627P-25mg)
5 mL Amber Glass Screw Cap Vial (860627P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 860627P-5MG | 04061835318728 |
| 860627P-25MG | 04061835318711 |